My Portfolio
+
LINK YOUR PORTFOLIO

Altimmune Inc ALT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 6:21 PM EDT
2.90quote price arrow up+0.03 (+1.05%)
Volume
12,159
Close
2.87quote price arrow down-0.03 (-1.03%)
Volume
2,994,339
52 week range
2.56 - 7.73
Loading...
  • Open2.93
  • Day High2.95
  • Day Low2.84
  • Prev Close2.90
  • 52 Week High7.73
  • 52 Week High Date06/25/25
  • 52 Week Low2.56
  • 52 Week Low Date05/01/26

Key Stats

  • Market Cap558.141M
  • Shares Out194.47M
  • 10 Day Average Volume2.65M
  • Dividend-
  • Dividend Yield-
  • Beta0.24

KEY STATS

  • Open2.93
  • Day High2.95
  • Day Low2.84
  • Prev Close2.90
  • 52 Week High7.73
  • 52 Week High Date06/25/25
  • 52 Week Low2.56
  • 52 Week Low Date05/01/26
  • Market Cap558.141M
  • Shares Out194.47M
  • 10 Day Average Volume2.65M
  • Dividend-
  • Dividend Yield-
  • Beta0.24

RATIOS/PROFITABILITY

  • EPS (TTM)-0.92
  • P/E (TTM)-3.11
  • Fwd P/E (NTM)-3.26
  • EBITDA (TTM)-96.812M
  • ROE (TTM)-42.75%
  • Revenue (TTM)36,000.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-253,002.80%
  • Debt To Equity (MRQ)12.15%

EVENTS

  • Earnings Date08/10/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects...
Jerome Durso
Chairman of the Board, President, Chief Executive Officer
Gregory Weaver
Chief Financial Officer
Address
910 Clopper Road, Suite 201S
Gaithersburg, MD
20878-1361
United States